

NEUROSCIENTIFIC PARTNERS WITH LINEAR CLINICAL RESEARCH FOR PHASE I CLINICAL STUDY

HIGHLIGHTS

- **NeuroScientific has partnered with market leading Perth-based Linear Clinical Research for Phase I trials of EmtinB™**
- **The Phase I trial will be a first-in-human study of EmtinB™ in healthy volunteers**
- **A Phase I ocular study in glaucoma patients is also planned for 2H 2021**

NeuroScientific Biopharmaceuticals Ltd (ASX: **NSB**) ("**NeuroScientific**" or "**the company**") is pleased to announce that it has partnered with Perth-based clinical contract research organisation Linear Clinical Research Ltd (**Linear**) to commence Phase I clinical trials with lead drug candidate EmtinB™ in the second half of 2021.

In what will be a historical milestone for the company, the planned Phase I clinical trial will be a first-in-human study of EmtinB™ in healthy volunteers with the primary end point of assessing safety, tolerability, and pharmacokinetics. With up to 90 participants set to be recruited and the inclusion of multiple dose cohorts, the study will be used to support future Phase II trials in Alzheimer's disease and Multiple sclerosis.

Also during the second half of this year, NeuroScientific is planning to undertake a Phase I trial of EmtinB™ in glaucoma patients, with EmtinB™ administered by intravitreal delivery.

The partnership with Linear follows the recent announcement of Paul Rennie as Non-executive Chairman of NeuroScientific, who brings a wealth of clinical experience to an already strong management team. Additional details about NeuroScientific's clinical development program will be provided in future company updates.

NeuroScientific's Managing Director Matt Liddelow commented: *"This partnership is a significant milestone for NeuroScientific and we are elated to be transitioning our R&D program into first-in-human trials with another leading-edge, WA-based company in Linear Clinical Research. The trial is also a significant milestone for the advancement of EmtinB™ as a potential disease-modifying drug for a range of neurodegenerative conditions that currently lack such treatments, including Alzheimer's disease and Multiple sclerosis".*

Linear's Chief Executive Officer Jayden Rogers commented: *"Linear is thrilled to play an active role with such an exciting and innovative WA-based biotechnology company and support their clinical development of EmtinB™ and assist in advancing a very promising and much needed treatment option for patients with debilitating neurodegenerative conditions".*

This announcement is authorised by the board of NeuroScientific Biopharmaceuticals Ltd.

-ENDS-

For more information please contact:

Matthew Liddelow
CEO and Managing Director
ml@neuroscientific.com
+ 61 8 6382 1805

Lucas Robinson
Investor Relations
Corporate Storytime
lucas@corporatestorytime.com
+ 61 408 228 889

About NeuroScientific Biopharmaceuticals Ltd

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinB™, a therapeutic peptide initially targeting Alzheimer's disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB™. For more information, please visit www.neuroscientific.com

About EmtinB™

EmtinB™ is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB™ is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury.

Our preclinical research has established that EmtinB™ is highly specific and selective for its target receptor, safe and well tolerated at high concentrations, and is able to penetrate the blood brain barrier. A series of Phase I clinical studies will be conducted to establish the safety profile of EmtinB™ in humans.

About Linear Clinical Research

Linear Clinical Research is a global leader in early-stage clinical trials and a subsidiary of the Harry Perkins Institute of Medical Research. Linear operates one of Australia's most active early phase trial centres and is considered a leader in clinical trial innovation and data systems. It has conducted over 300 early phase trials which includes one of the most active cancer trial teams in the Asia-Pacific. For more information visit Linear.